The development of effective anti-SARS-CoV-2 vaccines remains certainly crucial in the global fight against the coronavirus disease 2019 (COVID-19) pandemic. Initial randomized trials on vaccines excluded several categories, particularly immunocompromised individuals, cancer patients receiving or not immunosuppressive therapy or cytotoxic agents, transplanted subjects or those receiving supportive treatments with immunoglobulins or blood/plasma products.
Prospective, Case-Control Study of Serological Response after Two Doses of BNT162b2 anti-SARS-CoV-2 mRNA Vaccine in Transfusion-Dependent Thalassemic Patients
Sgherza, Nicola;Zucano, Stefania;Tarantini, Francesco;Vimercati, Luigi;Di Gennaro, Daniela;Vitucci, Carmen;Tafuri, Silvio;Musto, Pellegrino
2022-01-01
Abstract
The development of effective anti-SARS-CoV-2 vaccines remains certainly crucial in the global fight against the coronavirus disease 2019 (COVID-19) pandemic. Initial randomized trials on vaccines excluded several categories, particularly immunocompromised individuals, cancer patients receiving or not immunosuppressive therapy or cytotoxic agents, transplanted subjects or those receiving supportive treatments with immunoglobulins or blood/plasma products.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
